Skip to main content

About Johnson & Johnson

  • GRI
  • 2-1

    Organizational details

Our business

At Johnson & Johnson (J&J) (“the Company”), we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated and cured, where treatments are smarter and less invasive and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healtcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity.

Headquartered in New Jersey, U.S., our operating companies employ approximately 134,000 employees spread around the world. Our employees engage in the research and development, manufacture and sale of a broad range of Innovative Medicine and MedTech products that save lives and help change lives for the better every day. We work with more than 38,500 suppliers and hundreds of external manufacturers to support the development and manufacturing of our products worldwide.

Our Purpose

We blend heart, science and ingenuity to profoundly impact health for humanity.

Our Values

We are driven by Our Credo, a set of values and principles that, since 1943, has challenged and inspired us to put the needs and well-being of the people we serve first.

Innovative Medicine

  • Oncology
  • Immunology
  • Neuroscience
  • Pulmonary Hypertension
  • Cardiovascular, Metabolism, Other
  • Infectious Diseases


  • Surgery
  • Orthopaedics
  • Interventional Solutions
  • Vision

Financial results ($millions)*

R&D investment Total sales 2022 2023 $15,085 $14,135 $13,326 $16,370 $85,159 $79,990 62 Consecutive years ofdividend increases*** R&D investment Net earnings from continuing operations** Total sales 2022 2023 $15,085 $14,135 $13,326 $16,370 $85,159 $79,990 62 Consecutive years of dividend increases***

* 2022 data has been restated to reflect the separation of the Consumer Health business. For detailed financial performance, see Johnson & Johnson's 2023 Annual Report.

** GAAP earnings were negatively impacted by the $6.9 billion dollar charge related to the talc settlement proposal recorded in the first quarter of 2023.

*** Includes dividend increases in April 2024.

Sales by business segment ($millions)

MedTech Innovative Medicine $30,400 $54,759 MedTech Innovative Medicine $30,400 $54,759
Joseph Wolk, Executive Vice President, Chief Financial Officer, Johnson & Johnson (photo)

2023 was a strong year for Johnson & Johnson, thanks to our employees around the world who worked tirelessly to improve and advance health outcomes for patients in the near- and long-term. Based on a strong financial foundation and continued investments in breakthrough science and technology, we are confident in our ability to continue making a positive impact on healthcare.”

Joseph Wolk, Executive Vice President, Chief Financial Officer, Johnson & Johnson